Sanofi Obesity Drug Can Cause Mood Disorders: Study

Law360, New York (November 16, 2007, 12:00 AM EST) -- Sanofi-Aventis' plans to market its weight-loss drug Zimulti in the United States took another hit this week, with two new studies finding that the drug increases the risk of developing psychiatric disorders.

The drug, known as rimonabant and already sold in 21 countries under the brand name Acomplia, was approved by the European Medical Agency in June 2006. But a U.S. Food and Drug Administration advisory panel voted unanimously in June to deny approval of the drug, citing concerns about its effectiveness and safety.

A study...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.